Development of Itraconazole Topical formulation in Skin Cancer Treatment by Kolimi, Praveen
University of Mississippi 
eGrove 
Graduate Student Council Research Grants Graduate School 
3-15-2020 
Development of Itraconazole Topical formulation in Skin Cancer 
Treatment 
Praveen Kolimi 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/gsc_researchgrants 
 Part of the Pharmacology Commons 
Recommended Citation 
Kolimi, Praveen, "Development of Itraconazole Topical formulation in Skin Cancer Treatment" (2020). 
Graduate Student Council Research Grants. 11. 
https://egrove.olemiss.edu/gsc_researchgrants/11 
This Article is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for 
inclusion in Graduate Student Council Research Grants by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
Development of Itraconazole Topical formulation in Skin Cancer Treatment  
1. Overview:  I, Praveen Kolimi, pursuing a first-year graduate program at the department of 
pharmaceutics and drug delivery.  This Graduate Student Council (GSC) grant proposal focus on 
topical application of Itraconazole (ICZ) in skin cancer treatment. 
2. Intellectual Merit: 5.4 million skin cancer cases are reported each year in the United States. A 
study disclosed that one among five Americans are likely to develop skin cancer in their entire 
life9. Skin cancer can be distinguished into two types, malignant melanoma (MM) and non-
melanoma skin cancer (NMSC)1, 8. NMSC further classified into squamous cell carcinoma (SCC) 
and basal cell carcinoma (BCC)8, 10.  It was estimated that every year 2 million people are suffering 
from BCC and 80 per cent cases observed in NMSC4. Studies have demonstrated the hedgehog 
pathway is involved in BCC and melanoma development12, 16. Cyclopamine is a prototype drug 
which inhibits the hedgehog pathway in BCC and preclinical studies demonstrated cyclopamine 
as a potential drug for skin cancer treatment2.  However, cyclopamine was not effective in skin 
cancer clinically due to its low solubility and toxicity profile2, 13. Recently, cyclopamine 
derivatives vismodegib and sonidegib hedgehog pathway inhibitors have been approved by 
USFDA for skin cancer through the oral route of administration6. Studies have reported oral 
vismodegib, and sonidegib produced adverse effects, including muscle spasms, alopecia and 
weight loss11. On the same lines, oral formulations are difficult to administer to unconscious 
patients, taste cannot be masked and they can be bulky making it difficult to ingest making oral 
formulations a discomfort to cancer patients. Topical anti-cancer drug treatment would better and 
effective option for topical (skin) cancer treatments. Topical products offer patient compliance 
which of utmost importance especially to the cancer patients. As of now, in the market, only 5-
fluoro uracil and imiquimod drugs are available for treating skin cancer through topical route7. 
Although 5-fluoro uracil and imiquimod beneficial for treating skin cancer, these drugs exhibit 
adverse effects including skin irritation, hair loss, pain and changes in skin color. Recent clinical 
studies have demonstrated ICZ oral dose are effective in the treatment of BCC and proposed 
mechanism of action is hedgehog pathway inhibition. The ICZ is high safety profile drug and 
extensively used as an anti-fungal agent for two decades. To our best knowledge, there is no 
effective topical formulation available for skin delivery of ICZ in skin cancer treatment, and 
therefore, it is required to develop ICZ topical formulation. The current study is designed to 
develop a topical formulation of ICZ and evaluate its potential effects in the treatment of skin 
cancer in athymic mice models. 
3) External Opportunity:  
Recently, many researchers are focusing on repurposing drugs, especially in cancer 
chemotherapy5, 15. Anti-fungal drugs, including ICZ and posaconazole, both drugs, were shown 
very positive results in skin cancer treatment5, 14. Here, we conduct studies of ICZ via the topical 
route of administration in skin cancer induced athymic nude mice. After executing studies, will 
utilize this data and will write grant proposals to AAPS and other funding foundations. 
 
